Immune checkpoint inhibitors and timing of administration
- PMID: 35114125
- DOI: 10.1016/S1470-2045(22)00009-2
Immune checkpoint inhibitors and timing of administration
Conflict of interest statement
NDi reports consulting fees from Vivreon Gastroscience. AIV reports grants from UCSF Helen Diller Family Comprehensive Cancer Center and National Institute of Aging, leadership roles in American Society of Clinical Oncology, stock ownership by a family member in Midatech, Portola, and Corbus Pharmaceuticals, and former employment of a family member by J& J Innovations. NDu reports consulting and advisory roles for Pfizer, Merck, BMS, Neogenomics, Janssen, Astrazeneca, Genentech, and BI Oncology.
Comment in
-
Immune checkpoint inhibitors and timing of administration.Lancet Oncol. 2022 Feb;23(2):e55. doi: 10.1016/S1470-2045(21)00704-X. Lancet Oncol. 2022. PMID: 35114124 No abstract available.
Comment on
-
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.
-
Immune checkpoint inhibitors and timing of administration - Authors' reply.Lancet Oncol. 2022 Feb;23(2):e57. doi: 10.1016/S1470-2045(22)00023-7. Lancet Oncol. 2022. PMID: 35114126 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources